| 7.11 0.18 (2.6%) | 10-08 13:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.03 | 1-year : | 12 |
| Resists | First : | 8.58 | Second : | 10.27 |
| Pivot price | 6.96 |
|||
| Supports | First : | 5.84 | Second : | 4.86 |
| MAs | MA(5) : | 6.84  |
MA(20) : | 6.81 |
| MA(100) : | 8.38 |
MA(250) : | 12.12 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 24.7 |
D(3) : | 21.6 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 27.14 | Low : | 5.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SER ] has closed below upper band by 44.2%. Bollinger Bands are 22.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.96 - 6.98 | 6.98 - 7.01 |
| Low: | 6.46 - 6.49 | 6.49 - 6.52 |
| Close: | 6.88 - 6.92 | 6.92 - 6.98 |
Wed, 02 Oct 2024
Serina Therapeutics CDO Presents at Injectables Summit - TipRanks
Wed, 02 Oct 2024
Serina Therapeutics to Present at the 14th Annual Injectables Summit - GlobeNewswire
Fri, 20 Sep 2024
Serina Therapeutics director buys $88.2k in company stock By Investing.com - Investing.com South Africa
Thu, 12 Sep 2024
Serina Therapeutics Names Steven Ledger as Permanent CEO - TipRanks
Thu, 12 Sep 2024
Serina Therapeutics appoints new CEO with strategic goals - Investing.com
Wed, 04 Sep 2024
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 2.94e+006 (%) |
| Held by Institutions | 58.1 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.27e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 356.79 |
| Profit Margin | -220.9 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 580.3 % |
| Return on Equity (ttm) | -45.3 % |
| Qtrly Rev. Growth | 3.17e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 27520 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|